Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.